RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 CARE-MS II Follow-up: Improvements with Alemtuzumab Maintained for 4 Years
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 29
SP 10
OP 11
DO 10.1177/155989771429007
UL http://mdc.sagepub.com/content/14/29/10.abstract
AB Improvements in annualized relapse rate (ARR) and Expanded Disability Status Scale (EDSS) score were maintained throughout 4 years following treatment with alemtuzumab for 2 years in patients with relapsing-remitting multiple sclerosis (RRMS) who relapsed on prior therapy. This article presents data from the Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab trial [NCT00930553; Hartung H-P et al. ECTRIMS 2014 (poster P043)].